<unk>  has been shown to inhibit skin cancer growth, angiogenesis and tumor angiogenesis and improve survival in mice infected with H5N1. Anti-cancer effects have been also demonstrated in models of prostate cancer, breast cancer and osteosarcoma. Clinical trials of<unk>  in patients with basal cell carcinoma commenced in Australia in 2010. In 2013 it was reported that<unk>  was safe and well tolerated after single intratumoral injection at all doses. c-Jun expression was reduced in the excised tumors of all patients injected and tumor depth decreased in the majority. This was the first report of the clinical use of a DNAzyme. The outcome of two other clinical trials evaluating DNAzymes performed in Asia and Europe were reported in 2014 and 2015, the former assessing an Epstein–Barr virus latent membrane protein 1 targeting DNAzyme and the latter a DNAzyme targeting the transcription factor GATA3 which involved 7 trial sites. In both trials, there were no adverse events due to DNAzyme. There was demonstrable efficacy noted in nasopharyngeal cancer patients injected with LMP1 DNAzyme and allergic asthma patients following GATA3 DNAzyme inhalation.
Dz13
Lq2
COVAX-19
ZF2001
P14arf
AP-7 
YK-11
Ty21a